Paul W Spearman MD
Vice Chair for Clinical and Translational Research; Professor, Infectious Diseases
Join to View Full Profile
3333 Burnet Ave# ML7017Cincinnati, OH 45229
Phone+1 513-636-4578
Fax+1 513-636-7039
Dr. Spearman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Spearman is a pediatric infectious disease specialist at Cincinnati Children's Hospital Medical Center. He is Vice Chair for Clinical and Translational Research at Cincinnati Children's. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 34 years. Dr. Spearman's research program studies basic aspects of HIV virology, virus-host interactions, and vaccine development.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1990 - 1994
Ohio State University HospitalResidency, Internal Medicine, 1986 - 1990
University of Texas Southwestern Medical SchoolClass of 1986
Certifications & Licensure
OH State Medical License 1987 - 2026
IN State Medical License 2021 - 2025
KY State Medical License 2021 - 2024
GA State Medical License 2005 - 2017
TN State Medical License 1994 - 2007
American Board of Internal Medicine Infectious Disease
American Board of Pediatrics Pediatric Infectious Diseases
Clinical Trials
- Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents Start of enrollment: 2021 Aug 06
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- The CLIC/GEEC pathway regulates particle uptake and formation of the virus-containing compartment (VCC) in HIV-1-infected macrophages.Kathleen Candor, Lingmei Ding, Sai Balchand, Jason E Hammonds, Paul Spearman
Plos Pathogens. 2025-03-01 - Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.Hana M El Sahly, Evan J Anderson, Lisa A Jackson, Kathleen M Neuzil, Robert L Atmar
Vaccine. 2025-02-15 - A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.Christina A Rostad, Inci Yildirim, Carol Kao, Jumi Yi, Satoshi Kamidani
NPJ Vaccines. 2024-12-23
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
